Author

Pei‐Chang Lee

Hammersmith HospitalORCID 0000-0002-7492-2484Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Organism:human· 2 Approach:statistical model· 2 Assay:bulk RNA-seq· 1 Research Focus:gene regulatory network inference· 1 Assay:metabolomics· 1 Assay:metagenomics· 1

Frequent Co-Authors

Yi‐Hsiang HuangiD· 2 shared Ahmed Omar KasebiD· 1 shared Alessandro ParisiiD· 1 shared Andrea DalbeniiD· 1 shared Antonio D’AlessioiD· 1 shared Anwaar SaeediD· 1 shared Aria TorkpouriD· 1 shared Bernardo StefaniniiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

Yi‐Hsiang HuangORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

MicrobiologyMicrobiology SpectrumPeer-reviewedOct 26, 2026

Integrated microbiome and metabolomic profiling reveals alterations across the adenoma-colorectal cancer sequence

Tien-En Chang, Hung‐Hsin Lin, Jiing–Chyuan Luo…·Ming‐Chih Hou

This study identifies microbial and metabolic changes across the adenoma-carcinoma sequence in colorectal cancer using 16S rRNA sequencing and metabolomic profiling.

DOI 10.1128/spectrum.01059-26

humanmetagenomics

𝕏 PostBluesky

Cancer BiologybioRxivPreprintJul 8, 2025

Clinical and molecular characterisation of primary refractoriness to atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma.

Pasquale Lombardi, Erik Ramon‐Gil, Leonardo Brunetti…·David James Pinato

This study identifies clinical and molecular features of primary refractoriness to atezolizumab plus bevacizumab in HCC, showing poor outcomes and an immunosuppressive tumor microenvironment.

DOI 10.1101/2025.07.08.663653

humanbulk RNA-seq

𝕏 PostBluesky